{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:53:38Z","timestamp":1792688018442,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejim.2026.106727","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:43:14Z","timestamp":1772628194000},"page":"106727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-9755","authenticated-orcid":false,"given":"Richard","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gruev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoto","family":"Yotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-3721","authenticated-orcid":false,"given":"Peter","family":"Jackuliak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Domienik-Kar\u0142owicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Tykarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-593X","authenticated-orcid":false,"given":"Milosz J.","family":"Jaguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-5018","authenticated-orcid":false,"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-1393","authenticated-orcid":false,"given":"Marcin","family":"Barylski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Mamcarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0650-9361","authenticated-orcid":false,"given":"Zoltan","family":"Jarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Becer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-8779","authenticated-orcid":false,"given":"Drago\u0219","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"We\u0142nicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Widecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczyslaw","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.106727_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131779","article-title":"Relationship between hyperuricemia and the risk of cardiovascular events and chronic kidney disease in both the general population and hypertensive patients: A systematic review and meta-analysis","volume":"399","author":"Zheng","year":"2024","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2024.103796","article-title":"Hyperuricemia, A new cardiovascular risk","volume":"35","author":"Kuwabara","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.106727_bib0003","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ejim.2026.106727_bib0004","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5603\/CJ.2018.0116","article-title":"Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk","volume":"25","author":"Borghi","year":"2018","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/CJ.a2021.0001","article-title":"Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update","volume":"28","author":"Borghi","year":"2021","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/cj.98254","article-title":"Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update","volume":"31","author":"Borghi","year":"2024","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15010011","article-title":"Asymptomatic hyperuricemia and the kidney: lessons from the URRAH study","volume":"15","author":"Barnini","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.ejim.2026.106727_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132527","article-title":"Uric acid and metabolic syndrome: Importance of hyperuricemia cut-off","volume":"417","author":"Maloberti","year":"2024","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.ejim.2026.106727_bib0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020180","article-title":"Cumulative serum uric acid and its time course are associated with risk of myocardial infarction and all-cause mortality","volume":"10","author":"Tian","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.ejim.2026.106727_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000246","article-title":"Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog","volume":"4","author":"Bannasch","year":"2008","journal-title":"PLoS Genet"},{"issue":"6","key":"10.1016\/j.ejim.2026.106727_bib0011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.ackd.2012.07.009","article-title":"Renal transport of uric acid: evolving concepts and uncertainties","volume":"19","author":"Bobulescu","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"issue":"10","key":"10.1016\/j.ejim.2026.106727_bib0012","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ejim.2026.106727_bib0013","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol (Hob NJ)"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0014","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejim.2026.106727_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejim.2020.07.013","article-title":"Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome","volume":"82","author":"Centola","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.106727_bib0016","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.numecd.2021.01.023","article-title":"Uric acid in chronic coronary syndromes: relationship with coronary artery disease severity and left ventricular diastolic parameter","volume":"31","author":"Maloberti","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis: NMCD"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.numecd.2020.08.015","article-title":"Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage","volume":"31","author":"Maloberti","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis: NMCD"},{"issue":"5","key":"10.1016\/j.ejim.2026.106727_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40292-023-00602-4","article-title":"The Results of the URRAH (Uric Acid Right for Heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation","volume":"30","author":"Maloberti","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"9","key":"10.1016\/j.ejim.2026.106727_bib0019","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1024\/0040-5930.61.9.541","article-title":"[Physiology and biochemistry of uric acid]","volume":"61","author":"Hediger","year":"2004","journal-title":"Ther Umsch"},{"key":"10.1016\/j.ejim.2026.106727_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108615","article-title":"Uric acid in health and disease: From physiological functions to pathogenic mechanisms","volume":"256","author":"Wen","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ejim.2026.106727_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13091409","article-title":"The role of uric acid in human health: insights from the uricase gene","volume":"13","author":"Roman","year":"2023","journal-title":"J Pers Med"},{"issue":"17","key":"10.1016\/j.ejim.2026.106727_bib0022","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2026.106727_bib0023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","article-title":"Hyperuricemia and endothelial function: From molecular background to clinical perspectives","volume":"278","author":"Maruhashi","year":"2018","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ejim.2026.106727_bib0024","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/biomedicines10123067","article-title":"Hyperuricemia and endothelial function: is it a simple association or do gender differences play a role in this binomial?","volume":"10","author":"Ciarambino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejim.2026.106727_bib0025","article-title":"Inflammatory response to regulated cell death in gout and its functional implications","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0026","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12916-025-04195-8","article-title":"Physiological serum uric acid concentrations correlate with arterial stiffness in a sex-dependent manner","volume":"23","author":"Thews","year":"2025","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.ejim.2026.106727_bib0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"issue":"10","key":"10.1016\/j.ejim.2026.106727_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102062","article-title":"Uric acid-an emergent risk marker for thrombosis?","volume":"10","author":"\u021a\u0103poi","year":"2021","journal-title":"J Clin Med"},{"issue":"0","key":"10.1016\/j.ejim.2026.106727_bib0029","first-page":"15","article-title":"The role of uric acid in renal damage - a history of inflammatory pathways and vascular remodeling","volume":"5","author":"Russo","year":"2021","journal-title":"Vessel Plus"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/ijerph18020387","article-title":"Prevalence of hyperuricemia and the use of allopurinol in older poles\u2014Results from a population-based polsenior study","volume":"18","author":"Winder","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2026.106727_bib0032","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/01.hjh.0000835624.65401.d5","article-title":"Importance of uric acid threshold in its correlation with metabolic syndrome","volume":"40","author":"Maloberti","year":"2022","journal-title":"J Hypertens"},{"issue":"19","key":"10.1016\/j.ejim.2026.106727_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/nu14194095","article-title":"The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017","volume":"14","author":"Piao","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejim.2026.106727_bib0034","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/DMSO.S232377","article-title":"Converging relationships of obesity and hyperuricemia with special reference to metabolic disorders and plausible therapeutic implications","volume":"13","author":"Gong","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228684","article-title":"Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017","volume":"15","author":"Son","year":"2020","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.ejim.2026.106727_bib0036","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1097\/MD.0000000000001358","article-title":"Individuals with Type 2 diabetes mellitus are at an increased risk of gout but this is not due to diabetes: a population-based cohort study","volume":"94","author":"Wijnands","year":"2015","journal-title":"Med (Baltim)"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0037","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12889-025-21643-5","article-title":"Conducting genetic epidemiology research on hyperuricaemia and gout in an indigenous community in Guam - a feasibility study","volume":"25","author":"Paulino","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejim.2026.106727_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.560720","article-title":"Age and gender-specific reference intervals for uric acid level in children aged 5\u201314 years in Southeast Zhejiang Province of China: hyperuricemia in children may need redefinition","volume":"9","author":"Dai","year":"2021","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.ejim.2026.106727_bib0039","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/HJH.0000000000003109","article-title":"Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers","volume":"40","author":"Huck","year":"2022","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12882-024-03546-6","article-title":"The association of low serum uric acid with mortality in older people is modified by kidney function: National Health and Nutrition Examination Survey (NHANES) 1999\u20132018","volume":"25","author":"Fan","year":"2024","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0041","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res (Hob)"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0042","article-title":"Long-term cardiovascular risk and mortality associated with uric acid to HDL-C ratio: a 20-year cohort study in adults over 40","volume":"15","author":"Cui","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0043","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12872-019-1215-z","article-title":"Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants","volume":"19","author":"Rahimi-Sakak","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"33","key":"10.1016\/j.ejim.2026.106727_bib0044","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0045","article-title":"Serum uric acid\/serum creatinine ratio and cardiovascular mortality in diabetic individuals-the uric acid right for heart health (URRAH) project","volume":"14","author":"D'Elia","year":"2024","journal-title":"Metabolites"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13020244","article-title":"Serum uric acid predicts all-cause and cardiovascular mortality independently of hypertriglyceridemia in cardiometabolic patients without established CV disease: a sub-analysis of the uric acid right for heart health (URRAH) study","volume":"13","author":"Mengozzi","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.ejim.2026.106727_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.713652","article-title":"Serum uric acid and kidney disease measures independently predict cardiovascular and total mortality: the uric acid right for heart health (URRAH) project","volume":"8","author":"Russo","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0048","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejim.2026.106727_bib0049","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/HJH.0000000000003068","article-title":"The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study","volume":"40","author":"Ungar","year":"2022","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.ejim.2026.106727_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40292-024-00665-x","article-title":"Hyperuricemia in cardiac rehabilitation patients: prevalence and association with functional improvement and left ventricular ejection fraction","volume":"31","author":"Fortuna","year":"2024","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.ejim.2026.106727_bib0051","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1097\/01.hjh.0000572844.50613.9a","article-title":"Prognostic cut-off values of serum uric acid associated with fatal and non fatal incident myocardial infarction independently of arterial hypertension in a large cohort","volume":"37","author":"Casiglia","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2026.106727_bib0052","article-title":"Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan","volume":"9","author":"Akashi","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0053","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/HJH.0000000000002287","article-title":"Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study","volume":"38","author":"Casiglia","year":"2020","journal-title":"J Hypertens"},{"issue":"11","key":"10.1016\/j.ejim.2026.106727_bib0054","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41371-021-00613-5","article-title":"Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study","volume":"36","author":"Tikhonoff","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.46497\/ArchRheumatol.2025.10808","article-title":"Hyperuricemia and the risk of stroke incidence and mortality: A systematic review and meta-analysis","volume":"40","author":"Jiang","year":"2025","journal-title":"Arch Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0056","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/art.24164","article-title":"Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study","volume":"61","author":"Chen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ejim.2026.106727_bib0057","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/biomedicines13081838","article-title":"Causal relationship between serum uric acid and atherosclerotic disease: a mendelian randomization and transcriptomic analysis","volume":"13","author":"Wang","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejim.2026.106727_bib0058","doi-asserted-by":"crossref","first-page":"f4262","DOI":"10.1136\/bmj.f4262","article-title":"Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts","volume":"347","author":"Palmer","year":"2013","journal-title":"BMJ: Br Med J"},{"issue":"10359","key":"10.1016\/j.ejim.2026.106727_bib0059","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2026.106727_bib0060","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.ejim.2026.106727_bib0061","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/ckj\/sfac075","article-title":"Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?","volume":"15","author":"Leoncini","year":"2022","journal-title":"Clin Kidney J"},{"issue":"13","key":"10.1016\/j.ejim.2026.106727_bib0062","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"10264","key":"10.1016\/j.ejim.2026.106727_bib0063","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ejim.2026.106727_bib0064","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.3390\/ijms26189000","article-title":"Hyperuricemia in chronic kidney disease: emerging pathophysiology and a novel therapeutic strategy","volume":"26","author":"Takata","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-22831-4","article-title":"Prevalence and associated factors of hyperuricemia in chronic kidney disease: evidence from a single-center hospital-based study in Ethiopia, 2024","volume":"15","author":"Yirdaw","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0066","doi-asserted-by":"crossref","DOI":"10.5812\/numonthly.7(3)2015.27233","article-title":"Associations between hyperuricemia and chronic kidney disease: a review","volume":"7","author":"Prasad Sah","year":"2015","journal-title":"Nephrourol Mon"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0067","doi-asserted-by":"crossref","first-page":"249","DOI":"10.37349\/emed.2022.00089","article-title":"Hyperuricemia\u2014a serious complication among patients with chronic kidney disease: a systematic review and meta-analysis","volume":"3","author":"Rashid","year":"2022","journal-title":"Explor Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0068","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-019-43241-3","article-title":"Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study","volume":"9","author":"Oh","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0069","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244106","article-title":"The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: a health checkup cohort study","volume":"16","author":"Son","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41392-025-02497-0","article-title":"Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0071","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12882-024-03712-w","article-title":"Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study","volume":"25","author":"Steelandt","year":"2024","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106727_bib0072","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40620-025-02269-7","article-title":"Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review","volume":"38","author":"Kamel","year":"2025","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106727_bib0073","doi-asserted-by":"crossref","DOI":"10.5527\/wjn.v14.i1.99555","article-title":"Providing care for kidney transplant recipients: an overview for generalists","volume":"14","author":"Belal","year":"2025","journal-title":"World J Nephrol"},{"issue":"7","key":"10.1016\/j.ejim.2026.106727_bib0074","article-title":"Sodium-glucose cotransporter 2 inhibitors to decrease the uric acid concentration-a novel mechanism of action","volume":"10","author":"Kochanowska","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/gucdd2020014","article-title":"SGLT2 inhibitors and uric acid homeostasis","volume":"2","author":"Zapf","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"10","key":"10.1016\/j.ejim.2026.106727_bib0076","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"W\u00fcrzner","year":"2001","journal-title":"J Hypertens"},{"issue":"10","key":"10.1016\/j.ejim.2026.106727_bib0077","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ajh.2008.245","article-title":"Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients","volume":"21","author":"Hamada","year":"2008","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0078","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","article-title":"Effect of fenofibrate in combination with urate lowering agents in patients with gout","volume":"21","author":"Lee","year":"2006","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.106727_bib0079","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11906-006-0005-z","article-title":"Uric acid and hypertension","volume":"8","author":"Feig","year":"2006","journal-title":"Curr Hypertens Rep"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:17:03Z","timestamp":1776021423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":79,"alternative-id":["S0953620526000324"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106727","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106727"}}